Anzeige
Mehr »
Donnerstag, 26.06.2025 - Börsentäglich über 12.000 News
Blockbuster-Bohrergebnisse: Gold-Antimon-Fund in Nevada trifft geopolitischen Nerv
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N6VP | ISIN: US04335A1051 | Ticker-Symbol:
NASDAQ
25.06.25 | 21:59
7,790 US-Dollar
0,00 % 0,000
1-Jahres-Chart
ARVINAS INC Chart 1 Jahr
5-Tage-Chart
ARVINAS INC 5-Tage-Chart

Aktuelle News zur ARVINAS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.06.ARVINAS, INC. - 8-K, Current Report1
13.06.Arvinas Inc.: Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress2
06.06.Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval20
06.06.Pfizer, Arvinas submit marketing application for vepdegestrant to the FDA4
06.06.Arvinas stock rises on FDA submission with Pfizer5
06.06.Arvinas Announces Submission Of NDA With Its Partner Pfizer For Vepdegestrant350NEW YORK CITY (dpa-AFX) - Arvinas (ARVN) announced the submission of a New Drug Application to the FDA with its partner Pfizer (PFE), for vepdegestrant for the treatment of patients with ER+/human...
► Artikel lesen
ARVINAS Aktie jetzt für 0€ handeln
06.06.Arvinas and Pfizer seek FDA approval for breast cancer drug10
06.06.Arvinas Inc.: Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer229- This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published...
► Artikel lesen
05.06.Arvinas Inc.: Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting3
02.06.What Analysts Are Saying About Arvinas Stock10
02.06.ARVINAS, INC. - 8-K, Current Report2
02.06.Leerink stuft Arvinas-Aktie nach ASCO-Treffen herab4
02.06.Leerink cuts Arvinas stock rating post ASCO meeting1
31.05.Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H224
31.05.Arvinas Inc.: Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer257Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with...
► Artikel lesen
05.05.Where Arvinas Stands With Analysts9
05.05.Citi cuts Arvinas stock price target to $9.50, keeps neutral rating2
05.05.Arvinas stock rating cut, price target slashed to $11 at Truist2
02.05.Arvinas stock rating cut to hold at TD Cowen after trial cancellations2
02.05.Arvinas targets regulatory filing for Vepdegestrant in metastatic breast cancer by 20252
Weiter >>
76 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1